New! Sign up for our free email newsletter.
Science News
from research organizations

Ethiopian 7-year trial finds that childhood eye infection increases after antibiotic program ends

Date:
August 14, 2018
Source:
PLOS
Summary:
Continuous mass distribution of azithromycin in northern Ethiopia, where the childhood eye infection trachoma is a major cause of blindness, is effective in preventing recurrence of trachoma but does not eliminate the infection entirely.
Share:
FULL STORY

Continuous mass distribution of azithromycin in northern Ethiopia, where the childhood eye infection trachoma is a major cause of blindness, is effective in preventing recurrence of trachoma but does not eliminate the infection entirely, according to a new study in PLOS Medicine by Jeremy Keenan and colleagues from the University of California in San Francisco, USA and the Carter Center in Addis Ababa, Ethiopia and Georgia, USA.

Antibiotic prophylaxis has been used to limit mass outbreaks of bacterial infections, such as meningococcal meningitis and ocular chlamydia infection, known as trachoma, when vaccines or other prophylactic measures are not widely available.

In the current cluster-randomized study (TANA II), a subset of communities in northern Ethiopia that had participated in a 4-year long trachoma prevention trial (TANA I) of either annual or semi-annual azithromycin treatment, were newly assigned to receive either continued annual or semi-annual azithromycin treatment, or cessation of treatment. Participants were observed for another 3-5 years and assessed for ocular chlamydia prevalence compared to baseline within each intervention group.

Between November 2010 and May 2013, 48 communities, including 3,938 children aged 0-9 years at baseline, were included in the trial. In the communities assigned to continue azithromycin, mean antibiotic coverage was greater than 90%. In the discontinuation groups, the mean prevalence of infection increased from 8.3% (95% confidence interval 4.2% to 12.4%) at baseline to 14.7% (95% CI 8.7% to 20.8%, P=0.04) at 36 months. Ocular chlamydia prevalence in communities where mass azithromycin distribution was continued was 7.2% (95% CI 3.3 to 11.0%) at baseline and 6.6% (95% CI 1.1 to 12.0%, P=0.64) at 36 months, showing that despite a total of 7 years of mass azithromycin distribution, infection was not eliminated. Nonetheless, the 36-month prevalence of ocular chlamydia was significantly lower in communities continuing antibiotic treatment compared with those discontinuing treatment (P=0.03)

One limitation of the study is that the results may not apply to regions with lower prevalence of trachoma.

The authors conclude that "stopping mass azithromycin treatment in some severely affected areas is not realistic," and that "alternative strategies for trachoma elimination may be required for the most severely affected areas."


Story Source:

Materials provided by PLOS. Note: Content may be edited for style and length.


Journal Reference:

  1. Jeremy D. Keenan, Zerihun Tadesse, Sintayehu Gebresillasie, Ayalew Shiferaw, Mulat Zerihun, Paul M. Emerson, Kelly Callahan, Sun Y. Cotter, Nicole E. Stoller, Travis C. Porco, Catherine E. Oldenburg, Thomas M. Lietman. Mass azithromycin distribution for hyperendemic trachoma following a cluster-randomized trial: A continuation study of randomly reassigned subclusters (TANA II). PLOS Medicine, 2018; 15 (8): e1002633 DOI: 10.1371/journal.pmed.1002633

Cite This Page:

PLOS. "Ethiopian 7-year trial finds that childhood eye infection increases after antibiotic program ends." ScienceDaily. ScienceDaily, 14 August 2018. <www.sciencedaily.com/releases/2018/08/180814140518.htm>.
PLOS. (2018, August 14). Ethiopian 7-year trial finds that childhood eye infection increases after antibiotic program ends. ScienceDaily. Retrieved June 21, 2024 from www.sciencedaily.com/releases/2018/08/180814140518.htm
PLOS. "Ethiopian 7-year trial finds that childhood eye infection increases after antibiotic program ends." ScienceDaily. www.sciencedaily.com/releases/2018/08/180814140518.htm (accessed June 21, 2024).

Explore More

from ScienceDaily

RELATED STORIES